Report : North America Neoantigens Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Treatment (Combination Therapy and Mono Therapy) and Therapeutic Specialty (Gastrointestinal Cancer, Lung Cancer, Solid Tumor, Urinary Systems Cancers, Melanoma, Head and Neck Cancer, and Others)

Combination Therapy Segment to Dominate North America Neoantigens Market in 2023

According to a new market research study on “North America Neoantigens Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Treatment and Therapeutic Specialty,” is expected to reach US$ 501,233.14 thousand by 2028 from US$ 127,564.64 thousand in 2023. The market is estimated to grow at a CAGR of 31.5% from 2023 to 2028. The report provides trends prevailing in the North America neoantigens market along with the drivers and restraints pertaining to the market growth. Application of next-generation sequencing for neoantigen identification is the major factor driving the growth of the North America neoantigens market. However, possible side effects associated with neoantigen vaccines may hinder the growth of North America neoantigens market.

The impacts of COVID-19 pandemic are being felt across several markets in North America. Although the healthcare sector had witnessed SARS, H1N1, and other outbreaks in the last few years, the severity of the COVID-19 has made the situation more complicated due to its mode of transmission. North America has been witnessing growing number of COVID-19 cases since its outbreak. For instance, according to WHO, from January 3, 2020 to May 5, 2021, there have been 32,123,136 confirmed cases of COVID-19 with 572,190 deaths. The cases are also increasing in Mexico and Canada. In Mexico, the cases have reached to 2,355,985 with 218,007 deaths. Similarly, in Canada, there are about 1,257,328 COVID-19 cases, with 24,450 deaths reported so far. In the US, many doctors, hospitals, and other healthcare facilities are delaying or canceling the cancer procedures, surgeries, and sometimes screenings or other treatments, if it is not considered urgent, emergency, or life-threatening condition. Due to weak immune system, cancer patients are requested to follow social distancing norms as they are more prone to get infected with virus that causes COVID-19. More research is being conducted on COVID-19 vaccines other than any other disease vaccine. For instance, a research study on “Cancer therapy tool informs COVID-19 vaccines” was published on April 2020 in Icahn School of Medicine at Mount Sinai, New York, NY, USA. In this study, a computational tool was designed to predict candidate neoantigens for cancer vaccines, which helps in the formation of T-cell vaccines against SARS-CoV-2. Pharmaceutical companies are halting ongoing studies and delaying the launch of new trials. Therefore, owing to these points, the pandemic is likely to affect cancer vaccine market.

The market for neoantigens market is segmented into treatment, therapeutic specialty, and country. Based on treatment, the market is segmented into combination therapy, and mono therapy. In 2023, the combination therapy segment is estimated to have the largest share of the market. Based on therapeutic specialty, the market is segmented into gastrointestinal cancer, lung cancer, solid tumor, urinary systems cancers, melanoma, head and neck cancer, and others. In 2023, the gastrointestinal cancer segment is estimated to hold the largest share of the market. Based on country, the market is segmented into US, Canada, and Mexico. In 2023, the US is estimated to have the largest share of the market throughout the forecast period.

Advaxis, Inc., Gradalis, Inc., Gritstone Oncology, Medigene AG, Moderna, Inc., and Ziopharm Oncology, Inc are among the leading companies in the North America neoantigens market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in 2021, Gradalis confirmed that results from the VITAL clinical trial were released in The Lancet Oncology, demonstrating that Vigil front-line maintenance use was well accepted and resulted in increased recurrence-free survival (RFS) and overall survival (OS) in patients with BRCA1/2 -wt advanced ovarian cancer.

Contact Us
Contact Person: Sameer Joshi

Phone: +1-646-491-9876
Email Id:   

Download Free PDF Brochure